Hand of the Market
Screener
Sectors
Compare
Insider buys
Funds
 Screener

PCRX Pacira BioSciences, Inc.

Compare with sector and industry Screen the industry

Health Care · Pharmaceuticals & Biotechnology · data as of 2026-10-22 · latest quarter 2026-06-30, filed 2026-08-04

Market cap
$1.45B
P/E (trailing)
98.9×
P/E vs. sector
3.8×
FCF yield
11.2%
Avg daily $ volume
$19.5M
Days to next report
14
Quality checklist

4 of 6 checks passed · quarter ending 2026-06-30

  • ROIC at least 10%2.0%
  • Operating margin up over 3 years−4.5 pp
  • Free cash flow at least 80% of net income1226.4%
  • Share count up at most 5% in 3 years-14.2%
  • Net debt at most 3× EBITDA1.5×
  • Revenue grew over 3 years3.7%
Insider buying, last 90 days

No discretionary insider buying in the last 90 days.

Tracked funds, latest reports
Active managers
+$5.49M +0.5 pp of the company
3 buying · 0 selling · 3 holding
Mutual funds & ETFs
+$186.45K +0.0 pp of the company
1 buying · 0 selling · 2 holding

Each factor with its sector median and, where it's reported per quarter, its last 12 quarters.

Size & liquidity
PCRXSector12 quartersMarket cap$1.45B$9.67BEnterprise value$1.6B$10.41BAvg daily $ volume$19.5M$132.68MDaily turnover1.3%1.3%
Growth
PCRXSector12 quartersRevenue CAGR 3y3.7%9.5%11.1% → 3.7%Revenue CAGR 5y8.2%8.9%Revenue growth YoY6.2%8.7%-2.1% → 6.2%Revenue acceleration+1.2 pp+0.0 pp−2.1 pp → +1.2 ppFCF growth YoY53.3%5.9%40.5% → 53.3%FCF conversion1226.4%130.8%1865.2% → 1226.4%Forward growth (HoM est.)5.0%9.8%
Valuation
PCRXSector12 quartersP/E (trailing)98.9×27.6×P/E (forward, HoM est.)94.2×25.2×P/E vs. sector3.8×1.0×PEG (HoM est.)18.973.12EV/EBITDA15.3×17.5×EV/Sales2.2×3.3×FCF yield11.2%3.6%Dividend yield0.0%0.0%Shareholder yield10.3%1.2%
Quality
PCRXSector12 quartersQuality checks passed43ROIC2.0%9.2%2.2% → 2.0%Gross profitability47.5%32.6%30.4% → 47.5%Gross margin79.2%60.1%70.1% → 79.2%Gross margin Δ 3y+10.6 pp−0.1 pp+0.3 pp → +10.6 ppOperating margin2.7%10.6%6.7% → 2.7%Operating margin Δ 3y−4.5 pp+0.9 pp−4.7 pp → −4.5 ppDebt/equity0.5×0.7×0.8× → 0.5×Net debt/EBITDA1.5×2.0×4.5× → 1.5×Interest coverage1.3×4.9×1.6× → 1.3×Share count Δ 3y-14.2%-0.3%7.2% → -14.2%Stock compensation / revenue7.5%1.8%7.2% → 7.5%Accruals ratio-12.4%-4.3%-8.7% → -12.4%
Earnings & estimates
PCRXSector12 quartersDays to next report1413
Ownership & positioning
PCRXSector12 quartersInsider buys (90d)00Insiders buying (90d)00Insider net value (90d)$0$0Institutional ownership109.9%99.6%Institutional Δ QoQ−2.3 pp+1.1 ppConviction funds net buying—−0.0 ppActive managers net buying+0.5 pp+0.1 ppActive funds net buying+0.0 pp+0.0 ppDays to cover15.054.29Short % of shares out20.3%6.0%Short interest Δ+1.3 pp+0.1 pp

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Terms of use

Source: SEC EDGAR: Forms 4 (insider trades), 10-Q and 10-K (financials). Insider trades as filed (amendments applied); financial metrics computed by Hand of the Market from the companies' quarterly and annual reports. Each trade links to its filing.

Not investment advice. These signals are starting points for research, not recommendations. Data may contain errors or lag the filings.